Pfizer (PFE) News Today

Pfizer Inc. (NYSE: PFE) has been attracting buyers as regulatory and pipeline updates improve sentiment. The stock recently reached a new 52-week high near $29.02 and is trading above both its 50-day and 200-day moving averages. However, valuation concerns and uncertainty over the durability of the rally could limit additional upside.

• Positive Sentiment: The FDA approved Pfizer’s 2026–2027 COMIRNATY XFG COVID-19 vaccine formula for high-risk age groups. The approval supports continued vaccine revenue and adds to a series of positive developments that have helped lift PFE toward a two-year high. Pfizer After FDA Vaccine Approval Faces A Fair Value Reality Check
• Positive Sentiment: Pfizer granted Medicus Pharma a global license to develop, manufacture and commercialize PF-08046031, an early-stage CD228V antibody-drug conjugate targeting cancer. The agreement could generate more than $1 billion in payments, plus royalties, although the economics depend on future development and commercial milestones. Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
• Positive Sentiment: Investor attention is shifting toward Pfizer’s longer-term growth pipeline, particularly the obesity candidate berobenatide and next-generation oncology medicines intended to support growth from 2028 onward. Pfizer has also begun a Phase 1 study of asthma candidate PF-08103402, providing additional pipeline optionality. Pfizer’s Pipeline Strategy Centers on Obesity and Oncology
• Neutral Sentiment: Pfizer has gained roughly 25.6% over the past year and 13.4% over the past month. Articles debate whether the shares remain a bargain or are now fairly valued, suggesting that further gains will require stronger earnings or pipeline execution rather than simply a valuation re-rating. Pfizer Stock Looks Fully Valued As Earnings Run Ahead Of Value
• Neutral Sentiment: Unusually high options volume and optimistic Wall Street coverage indicate elevated trading interest, but these signals do not establish a fundamental change in Pfizer’s earnings outlook. Pfizer Sees Unusually High Options Volume
• Negative Sentiment: Some commentary warns that the recent recovery may already reflect the vaccine approval and pipeline optimism. Concerns include Pfizer’s post-pandemic revenue pressure, future patent expirations and whether its AI, obesity and oncology strategy can offset declining legacy products. Can AI Save Pfizer Stock Before Its Patent Cliff Hits?